Anumana wins FDA breakthrough status for AI algorithm to detect PH
Related Articles
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
AI Algorithm Aids Early Detection of Low Ejection Fraction
Health Day: An artificial intelligence (AI) algorithm that uses data from electrocardiography can help increase the diagnosis of low ejection fraction (EF), according to a study published online May 6…May 27, 2021
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
IT Business Net: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT)…July 06, 2022
FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI
Pharma File: Anumana has announced the FDA had granted breakthrough Device Designation to its AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. Breakthrough Device Designations recognise novel innovations demonstrating potential…May 24, 2022